Chen Yin1†
Bing Xiao- 1Department of Cardiac Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China
- 2Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
- 3Department of Physiology, Hebei Medical University, Shijiazhuang, China
Background: Sepsis after cardiac surgery represents a severe perioperative complication with high incidence and mortality rates. While the cardioprotective benefits of β-blocker following cardiac surgery are widely recognized, their impact on sepsis development remains unclear. This study aims to investigate the association between early postoperative β-blocker use and the incidence of sepsis, as well as clinical outcomes, in patients undergoing cardiac surgery.
Methods: The analysis incorporated data from the MIMIC-IV database, with confounding factors addressed through propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and overlap weighting (OW). Logistic regression models assessed the risk of sepsis and in-hospital mortality, while Cox proportional hazards models evaluated 28-day and 1-year mortality. Kaplan-Meier survival curves and log-rank tests compared survival between groups. Sensitivity analyses using Fine-Gray competing risk models and cumulative incidence functions were performed. Subgroup analyses explored heterogeneity of treatment effects, and metoprolol was further stratified by dose to assess dose-response relationships.
Results: A total of 3,154 patients treated with β-blocker and 5,220 controls were included. Early β-blocker use was associated with a reduced risk of sepsis and lower in-hospital mortality across all methods. For 28-day and 1-year mortality, β-blocker use showed a trend toward risk reduction. Competing risk analyses demonstrated lower cumulative incidence of sepsis in the β-blocker group. Subgroup and dose-response analyses indicated that both low and high doses of metoprolol were associated with reduced postoperative sepsis risk and mortality outcomes.
Conclusion: Early use of β-blocker after cardiac surgery was associated with a lower incidence of sepsis, with potential benefits observed in both short-term and long-term prognosis. These findings provide valuable evidence for optimizing perioperative drug management strategies.
1 Introduction
Postoperative sepsis is one of the severe complications in the perioperative period following cardiac surgery (Howitt et al., 2018; Lagrost et al., 2014). A retrospective study based on the Sepsis-3 diagnostic criteria revealed that, among cardiac surgery patients admitted to the intensive care unit (ICU), both suspected and confirmed sepsis patients had significantly longer ICU stays and higher mortality rates compared to those without evidence of infection. Specifically, the 30-day mortality rate among confirmed sepsis patients was increased by 6.6-fold (Howitt et al., 2018). Due to prolonged surgical procedures and the use of cardiopulmonary bypass (CPB), patients undergoing cardiac surgery were more prone to inflammatory responses and organ dysfunction (Squiccimarro et al., 2019; Paparella et al., 2002). Despite a range of perioperative management strategies currently in use (Whitlock et al., 2015; Goetz et al., 2021), and multiple prediction models for adverse events after cardiac surgery have been developed (Luo, 2024), no specific pharmacological interventions have been developed to target sepsis related to cardiac surgery. Given the poor prognosis caused by sepsis (Peng et al., 2024; Martin-Loeches et al., 2024), it is particularly urgent to explore effective drug treatment regimens.
Surgical stress-induced sympathetic activation has been recognized as a key mechanism affecting immune status in these patients. During the perioperative period, activation of the hypothalamus-pituitary-adrenal (HPA) axis and the sympathoadrenal system (SAS) promotes the release of cortisol and catecholamines (Marik and Flemmer, 2012). Since multiple immune cells express adrenergic receptors on their surfaces (Schiller et al., 2021; Lorton and Bellinger, 2015), these stress hormones engage receptor-mediated signaling pathways that disrupt the balance of immune cell quantity and function. Moreover, they stimulate immune cells to produce and release both pro-inflammatory and anti-inflammatory mediators, thereby increasing susceptibility to infection (Marik and Flemmer, 2012; Wang et al., 2005).
β-blocker, commonly used as part of perioperative care medications after cardiac surgery, have been well-established for their cardioprotective effects (Bello et al., 2023; Lindgren et al., 2022). Emerging evidence suggests that β-blocker may also play a significant role in modulating immune responses. Previous studies have indicated that septic patients receiving chronic β-blockers therapy tend to experience relatively less severe disease conditions (Hasegawa et al., 2022; Tan K. et al., 2021). Furthermore, an animal experiment has confirmed that intraoperative administration of esmolol can attenuate the systemic inflammatory response after pneumonectomy (Garutti et al., 2019). However, there is currently a lack of cohort study investigating whether early postoperative β-blocker use can reduce the incidence of sepsis after cardiac surgery.
Therefore, we conducted a retrospective cohort study to examine the association between early postoperative β-blockers use and sepsis development in cardiac surgery patients, aiming to provide insights for optimizing perioperative pharmacological strategies to prevent this serious complication.
2 Materials and methods
2.1 Data sources and study design
This study utilized data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV, version 3.1) (Johnson et al., 2023), encompassing patient information collected at Beth Israel Deaconess Medical Center spanning from 2008 to 2022, including 94,458 ICU admissions. The database was stored in PhysioNet (https://physionet.org/) (Goldberger et al., 2000); due to its strict de-privacisation procedures, patient informed consent was not required. The corresponding author obtained the necessary database access by completing the Collaborative Institutional Training Initiative (CITI) program exam (Record ID: 57440109). Patients meeting all of the following criteria were eligible for inclusion (Supplementary Figure S1): having undergone cardiac surgery (including valve surgery, coronary artery bypass grafting, or combined procedures) during their hospital stay and being over 18 years of age. For patients with multiple ICU admissions, only the first admission was considered. We extracted comprehensive clinical variables from the first day of ICU admission. Baseline characteristics included gender, race, age, body mass index (BMI). Past medical history comprised myocardial infarction (MI), hypertension, atrial fibrillation (AF), kidney disease, lung disease, liver disease, diabetes, malignancy and rheumatic disease. Laboratory test indicators encompassed white blood cell (WBC), red blood cell (RBC), platelet, hemoglobin, red cell distribution width (RDW), hematocrit, international normalized ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT), anion gap, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, sodium, calcium, potassium, magnesium, chloride, N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, basophils, eosinophils, lymphocytes, monocytes, neutrophils, lactic acid and urine output. Vital signs consisted of oxygen partial pressure (PO2), carbon dioxide partial pressure (PCO2), PH, total carbon dioxide (Total CO2), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MBP), central venous pressure (CVP), respiratory rate (RR), percutaneous arterial oxygen saturation (SpO2) and temperature. Therapeutic interventions were recorded, including the administration of vasoactive drugs, angiotensin converting enzyme inhibitors (ACEI), glucocorticoid, anticoagulant, antibiotics, diuretics, and β-blocker, as well as the implementation of renal replacement therapy (RRT) and mechanical ventilation. The Sequential Organ Failure Assessment (SOFA) score, Charlson Comorbidity Index, Simplified Acute Physiology Score III (Apsiii) and Oxford acute severity of illness score (Oasis) were also obtained on the first ICU day. For parameters with multiple measurements, the first recorded value was used for analysis. Early β-blocker use was defined as prescription within the first day after cardiac surgery. Patients who received prescriptions after the diagnosis of sepsis were excluded. The primary endpoint was the incidence of sepsis in the ICU, diagnosed according to the Sepsis-3 criteria. The secondary endpoints included in-hospital mortality, 28-day mortality, and 1-year mortality.
2.2 Statistical analysis
To address potential confounding factors, we employed propensity score matching (PSM), inverse probability of treatment weighting (IPTW) and overlap weighting (OW) methods. For PSM, the MatchIt package (version 4.7.0) was used to perform 1:1 nearest neighbor matching with a caliper width of 0.2 standard deviations. The IPTW approach involved calculating propensity scores via logistic regression, which were then used to assign weights to patients for subsequent analyses. The OW emphasized the population where treatment groups overlapped, with weights proportional to the probability of assignment to the opposite treatment group, thereby automatically eliminating extreme weights. Continuous variables’ distribution was evaluated using the Kolmogorov-Smirnov test, with normally distributed variables expressed as mean ± standard deviation (SD) and non-normally distributed variables as median (interquartile range). Kruskal–Wallis tests were used for between-group comparisons of continuous variables, while Pearson’s chi-square tests were applied to categorical variables expressed as frequencies (proportions). We assumed that the data were Missing at Random (MAR), calculated the missingness ratio for each variable, and removed those with a missing rate exceeding 20% (Supplementary Figure S2). Data preprocessing included handling extreme outliers based on the 1.5 times interquartile range rule and handling missing data through multiple imputations (10 imputations) using chained equations (MICE). Logistic regression was employed to assess the association between early β-blocker use and in-hospital sepsis and mortality, while Cox proportional hazards models were used to evaluate 28-day and 1-year mortality outcomes. Kaplan-Meier curves were utilized to observe survival patterns, with comparisons made using the log-rank test. Additionally, prespecified subgroup analyses were performed to examine heterogeneity of treatment effects across different populations. Regression analysis included all matching variables to ensure the robustness of the results. The competitive risk of sepsis occurrence was evaluated using a competitive risk model, specifically the Fine-Gray model. Patients who received metoprolol treatment were screened and retained for analysis, and the association between different doses and clinical outcomes was examined. All statistical analyses were carried out using R software (version 4.3.3), with statistical significance set at a two-sided P-value <0.05.
3 Results
This study included 3,154 patients treated with β-blocker and 5,220 control patients. Significant differences were observed in baseline characteristics between the two groups (Supplementary Table S1). From the perspective of demographic characteristics, the β-blocker group had a higher proportion of males, younger age, and greater BMI compared to the control group. Regarding laboratory parameters, the β-blocker group exhibited lower levels of WBC, RDW, BUN, chloride, magnesium, sodium, and creatinine, as well as improved coagulation function (lower INR, PT, and PTT) compared to the control group. Conversely, the β-blocker group had higher levels of RBC, hemoglobin, hematocrit. Hemodynamic parameters revealed that the β-blocker group had lower HR, higher SBP, DBP, and MBP compared to controls. In terms of comorbidities and complications, the β-blocker group presented with lower Charlson comorbidity index, SOFA, Apsiii, Oasis, and a lower prevalence of AF, chronic pulmonary disease, chronic kidney disease, chronic liver disease, and sepsis. However, this group had a higher proportion of patients with MI, hypertension and diabetes. The β-blocker group also had greater use of diuretics and ACEI but a lower requirement for mechanical ventilation and vasoactive drugs. Analysis of clinical outcomes indicated that the β-blocker group experienced lower in-hospital, 28-day, and 1-year mortality, accompanied by shorter hospital and ICU stays compared to the control group. Standardized mean difference (SMD) analysis suggested that most of these differences were clinically relevant (SMD >0.1). Figure 1 showed the application characteristics of β-blocker. The majority of patients received β-1 blockers (96%), with metoprolol being the primary agent (93.8%). Oral administration (PO) was the predominant route (75.9%), while intravenous (IV) and mixed routes were used less frequently. The distribution of dosing was nearly balanced, with 49.6% of patients receiving a low dose (≤25 mg) and 50.8% receiving a high dose (>25 mg).
Figure 1. Distribution of early β-blocker.
To assess the balancing effects of PSM, IPTW, and OW, we conducted evaluations by comparing changes in SMD before and after adjustment (Figure 2; Supplementary Tables S2–S4). The results revealed baseline imbalances between the β-blocker group and the control group in the original data, with most variables exhibiting SMD values exceeding the 0.1 threshold. However, after adjustment using PSM, IPTW, and OW methods, the SMD values for most of variables were reduced to below 0.1.
Figure 2. Covariate balance assessment across different matching methods. BMI, body mass index; WBC, white blood cell; RBC, red blood cell; RDW, red cell distribution width; INR, international normalized ratio; PT, prothrombin time; PTT, partial thromboplastin time; BUN, blood urea nitrogen; PO2, oxygen partial pressure; PCO2, carbon dioxide partial pressure; Total CO2, total carbon dioxide; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; RR, respiratory rate; SpO2, percutaneous arterial oxygen saturation; SOFA, Sequential organ failure score; Apsiii, Simplified Acute Physiology Score III; Oasis, Oxford acute severity of illness score; MI, myocardial infarction; AF, atrial fibrillation; RRT, renal replacement therapy.
The Kaplan-Meier survival analysis within the PSM cohort demonstrated that the 28-day survival rate was significantly higher in the β-blocker group compared to the control group (Figure 3A, P = 0.0046). This survival benefit persisted throughout the entire 1-year follow-up period (Figure 3D, P = 0.0063). These findings were further corroborated by IPTW analysis, which showed significantly higher survival rates in the β-blocker group at both 28 days (Figure 3B, P < 0.001) and 1 year (Figure 3E, P < 0.001). Similarly, overlap weighting analysis consistently confirmed the survival advantage for the β-blocker group at both 28-day (Figure 3C, P < 0.001) and 1-year mortality (Figure 3F, P < 0.001).
Figure 3. Kaplan-Meier survival curves using different propensity score methods. (A–C) 28-day survival curves using PSM, IPTW, and OW methods, respectively. (D–F) 1-year survival curves using PSM, IPTW, and OW methods, respectively. PSM, propensity score matching; IPTW, inverse probability of treatment weighting; OW, overlap weighting.
The clinical benefits were consistently demonstrated in multivariable-adjusted analyses (Table 1). All three models showed a marked reduction in sepsis risk with β-blocker treatment (pooled OR ≈ 0.13, all P < 0.001). Likewise, β-blocker use correlated with decreased in-hospital mortality (OR range: 0.455–0.506, P = 0.002–0.04). A similar protective effect was observed for 28-day mortality (HR range: 0.598–0.808, all P < 0.05), and this survival benefit extended to 1-year mortality (HR range: 0.784–0.806, all P < 0.05).
Table 1. Clinical outcomes across different propensity score methods.
To evaluate the heterogeneity of β-blocker treatment effects across various subgroups, a prespecified subgroup analysis was performed (Figure 4). The results indicated that the treatment effects of β-blocker remained consistent across most subgroups. We conducted a sensitivity analysis to examine the association between β-blocker use and postoperative sepsis using a competitive risk model. Fine-Gray subquantile risk regression was applied, treating in-hospital deaths as competing events, to analyze the impact of β-blocker use on sepsis risk. The results showed that the cumulative incidence of sepsis in the β-blocker use group was significantly lower than that in the control group (Supplementary Figure S4). In the competitive risk regression analysis, the adjusted subdistribution hazard ratio (SHR) for β-blocker use was 0.25 (95% CI: 0.22–0.28), suggesting an association between β-blocker use and reduced sepsis risk. Supplementary Figure S5 presented the dose-specific subgroup analyses. Both low and high doses of metoprolol were associated with lower postoperative sepsis compared with nonusers. This pattern was consistent across all measured outcomes, including in-hospital mortality, 28-day mortality, and 365-day mortality, where both dosing regimens showed protective effects but the magnitude of benefit was generally bigger in the low-dose group.
Figure 4. Subgroup analysis of clinical outcomes associated with β-blocker treatment. MI, myocardial infarction; AF, atrial fibrillation; RRT, renal replacement therapy; OR, odds ratio; HR, hazard ratio.
4 Discussion
We conducted a retrospective study to investigate the impact of early postoperative β-blocker use on the occurrence and prognosis of sepsis. Our results revealed that early administration of beta-blockers was associated with a reduced incidence of sepsis after cardiac surgery, and improved inpatient mortality, 28-day mortality, and 1-year mortality rates. These associations remained robust after adjusting for confounding factors using three statistical methods, including PSM, IPTW, and OW. Moreover, subgroup analysis indicated that the beneficial effects of β-blocker were consistent across most patient populations. Sensitivity analyses using competing risk models confirmed the robustness of these associations. Dose-response analysis showed that both low and high doses of metoprolol were associated with reduced sepsis risk, with low-dose groups also demonstrating favorable trends in mortality outcomes. These findings suggest that early β-blocker therapy might be an effective strategy to reduce the risk of sepsis and improve prognosis during the perioperative period following cardiac surgery.
Despite some advancements in reducing systemic inflammatory responses, such as improvements in CPB equipment, ultrafiltration/hemofiltration, and cytokine hemadsorption techniques, CPB-associated tissue/organ dysfunction and inflammatory complications, remain inadequately addressed (Mangoush et al., 2007; Dekker et al., 2020; Journois et al., 1994; Becker et al., 2023). Surgical site infections continue to pose a significant challenge, even with the implementation of various preventive measures targeting infection and bleeding control (Pradeep et al., 2021). Given the high mortality rate associated with sepsis (Rudd et al., 2020), identifying effective interventions to comprehensively address these critical postoperative complications is imperative.
As mentioned above, cardiopulmonary bypass (CPB) during cardiac surgery is a major factor inducing systemic inflammatory response syndrome (SIRS). Blood contact with the artificial surfaces of the extracorporeal circuit may activate multiple pro-inflammatory cascade reactions, thereby increasing the risk of infection and organ dysfunction (Day and Taylor, 2005; Suleiman et al., 2008). In recent years, studies have found that β-blocker, beyond their traditional cardioprotective effects, possess potential anti-inflammatory properties. Wong et al. reported that carvedilol (CVL) can prevent lysosomal and mitochondrial dysfunction, reduce ASC oligomerization, induce autophagy through a SIRT1-dependent pathway, and inhibit the activation of the NLRP3 inflammasome (Wong et al., 2018). Furthermore, carvedilol has been shown to inhibit oxidative stress and apoptosis by activating the Nrf2/ARE signaling pathway (Zhang et al., 2022). Another critical factor was the elevation of endotoxin levels during CPB, which contributed to increased postoperative infection risk (Kats et al., 2011; Klein et al., 2011). Studies have shown that patients undergoing CPB experience inadequate intestinal perfusion, leading to a significant increase in intestinal permeability that can persist beyond 24 h postoperatively (Rocke et al., 1987; Riddington et al., 1996). Early research confirmed this phenomenon by monitoring dynamic changes in lipopolysaccharide concentrations in venous blood of CPB patients (Ohri et al., 1993). As a key inflammatory trigger, endotoxin can activate both humoral and cellular mediator systems, initiating a cytokine cascade reaction typically characterized by the early release of TNF-α, which subsequently induces the expression of pro-inflammatory cytokines such as IL-6 and IL-8. These endotoxin-induced inflammatory responses elicit systemic compensatory mechanisms including neuroendocrine responses (Lowry, 2005). Notably, recent research has found that β-1 blocker can attenuate both systemic and local inflammatory responses in open abdominal surgery via a cholecystokinin receptor-dependent mechanism, while maintaining the integrity of intestinal barrier function (Tan S. et al., 2021). Furthermore, stress responses trigger a surge in catecholamines release, which binds to beta-adrenergic receptors (β-AR) on cell surfaces, activating downstream signaling pathways that adversely affect soft tissue wound healing processes (Jia et al., 2024). These effects include prolonged neutrophil retention at the wound site, excessive secretion of inflammatory factors, inhibition of ERK phosphorylation impeding keratinocyte migration, suppression of angiogenesis, altered fibroblast function, and upregulated expression of matrix metalloproteinases (MMPs) (Dasu et al., 2014; Yang et al., 2021; Kruk et al., 2019; Chay et al., 2016). This series of cascade reactions ultimately impairs the wound healing process, suggesting that β-blocker may exert a positive influence on wound healing.
Although we applied a competing risk model (Fine-Gray model) to account for competing effects such as death, the positive effect size for β-blocker use in sepsis risk reduction remained low (SHR: 0.25, 95% CI: 0.22–0.28). This implied that competing risk alone might not fully explain the weak association. While few studies have specifically examined β-blockers’ impact on postoperative sepsis risk, existing evidence indicates that early β-blocker use might exert anti-inflammatory effects by reducing circulating inflammatory proteins and suppressing pro-inflammatory cytokines like IL-6 (El-Menyar et al., 2024; Ogawa et al., 2013; Sezai et al., 2012). Unfortunately, the absence of key inflammatory biomarkers, including IL-6 and CRP, in our database limited further exploration of potential associations between cytokine levels and β-blocker use in this patient cohort. In additional, the analysis might be confounded by selection bias, as patients receiving β-blocker typically have more favorable baseline prognoses. Retrospective diagnosis could further distort findings through false-positive cases, particularly among cardiac surgery patients receiving antibiotics or blood cultures. Therefore, although sensitivity analyses including competing risk models yielded consistent results, the observed association and its effect size require cautious interpretation. Prospective studies remain necessary to establish whether β-blocker genuinely protect against postoperative sepsis and to determine their clinical utility.
In evaluating in-hospital mortality and long-term prognosis, our study demonstrated that early β-blocker administration was significantly associated with a reduction in both short-term and long-term mortality. These findings were robust across multiple analytical approaches highlighting the potential clinical value of β-blocker in the postoperative management of patients at risk for sepsis. While current studies lack full consensus, exposure to β-blocker prior to sepsis onset has shown prognostic benefits (Fuchs et al., 2017), and accumulating evidences support their therapeutic application during sepsis to improve clinical outcomes (Tan K. et al., 2021; Kuo et al., 2021). Therefore, the potential benefits of early postoperative β-blocker use deserve further validation through prospective studies in the future.
Dose-response analysis revealed that both low and high doses of β-blocker were associated with a reduction in sepsis risk; however, the magnitude of benefit was more pronounced in the low-dose group. These findings suggest that lower doses of metoprolol may be sufficient to confer clinical benefit, and escalating the dose may not yield additional protective effects. This observation was consistent with previous studies in other clinical settings, such as acute myocardial infarction, where higher doses of β-blockers have not demonstrated superior outcomes compared to lower doses (Allen et al., 2017; Hwang et al., 2019). Furthermore, current guidelines advise against the routine use of high-dose β-blockers during the perioperative period of non-cardiac surgery (Smilowitz et al., 2020). Therefore, rational selection of β-blocker dose is crucial for optimizing patient prognosis.
Several limitations to this study should be acknowledged. Firstly, the retrospective nature of the study using the MIMIC-IV database introduces the possibility of selection bias and the influence of unknown confounding factors. Although we employed multiple statistical techniques to mitigate confounding, residual biases cannot be fully excluded. Secondly, the relative effects and duration of specific β-blocker classes need further study. Meanwhile, future research should incorporate a series of measurements to better capture the dynamic changes of patients. Finally, prospective randomized controlled trials are necessary to validate these findings and to confirm their generalizability to broader patient populations. Caution is advised when extrapolating our results beyond the studied cohort.
5 Conclusion
Early use of β-blocker after cardiac surgery was associated with a lower incidence of sepsis, and potential benefits were shown in both short-term and long-term prognosis. These findings were consistently validated across multiple statistical methods, providing valuable evidence to guide the optimization of perioperative drug management strategies.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article because the study was carried out in accordance with the Declaration of Helsinki. Due to the de-identification of the MIMIC repository, sensitive data is not involved.
Author contributions
CY: Software, Writing – original draft, Data curation, Investigation. CG: Investigation, Writing – original draft, Data curation, Software. QM: Writing – review and editing, Formal Analysis, Visualization. SZ: Formal Analysis, Visualization, Writing – review and editing. QC: Writing – review and editing, Formal Analysis, Visualization. BX: Project administration, Conceptualization, Writing – review and editing, Supervision, Funding acquisition.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The project was supported by the S.T Program of Hebei No. 22377728D.
Acknowledgments
We thank all the staff who collected, organized and maintained the MIMIC database.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1615868/full#supplementary-material
References
Allen, J. E., Knight, S., McCubrey, R. O., Bair, T., Muhlestein, J. B., Goldberger, J. J., et al. (2017). β-blocker dosage and outcomes after acute coronary syndrome. Am. Heart J. 184, 26–36. doi:10.1016/j.ahj.2016.10.012
Becker, S., Lang, H., Vollmer Barbosa, C., Tian, Z., Melk, A., and Schmidt, B. M. W. (2023). Efficacy of CytoSorb®: a systematic review and meta-analysis. Crit. Care 27 (1), 215. doi:10.1186/s13054-023-04492-9
Bello, C., Rössler, J., Shehata, P., Smilowitz, N. R., and Ruetzler, K. (2023). Perioperative strategies to reduce risk of myocardial injury after non-cardiac surgery (MINS): a narrative review. J. Clin. Anesth. 87, 111106. doi:10.1016/j.jclinane.2023.111106
Chay, A., Zamparo, I., Koschinski, A., Zaccolo, M., and Blackwell, K. T. (2016). Control of βAR- and N-methyl-D-aspartate (NMDA) receptor-dependent cAMP dynamics in hippocampal neurons. PLoS Comput. Biol. 12 (2), e1004735. doi:10.1371/journal.pcbi.1004735
Dasu, M. R., Ramirez, S. R., La, T. D., Gorouhi, F., Nguyen, C., Lin, B. R., et al. (2014). Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: a recipe for impaired wound healing. Stem Cells Transl. Med. 3 (6), 745–759. doi:10.5966/sctm.2013-0200
Day, J. R., and Taylor, K. M. (2005). The systemic inflammatory response syndrome and cardiopulmonary bypass. Int. J. Surg. 3 (2), 129–140. doi:10.1016/j.ijsu.2005.04.002
Dekker, N. A. M., Veerhoek, D., van Leeuwen, A. L. I., Vonk, A. B. A., van den Brom, C. E., and Boer, C. (2020). Microvascular alterations during cardiac surgery using a heparin or phosphorylcholine-coated circuit. J. Cardiothorac. Vasc. Anesth. 34 (4), 912–919. doi:10.1053/j.jvca.2019.10.012
El-Menyar, A., Asim, M., Khan, N., Rizoli, S., Mahmood, I., Al-Ani, M., et al. (2024). Systemic and cerebro-cardiac biomarkers following traumatic brain injury: an interim analysis of randomized controlled clinical trial of early administration of beta blockers. Sci. Rep. 14 (1), 19574. doi:10.1038/s41598-024-70470-y
Fuchs, C., Wauschkuhn, S., Scheer, C., Vollmer, M., Meissner, K., Kuhn, S. O., et al. (2017). Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br. J. Anaesth. 119 (4), 616–625. doi:10.1093/bja/aex231
Garutti, I., Rancan, L., Abubakra, S., Simón, C., Paredes, S. D., Ortega, J., et al. (2019). Effects of intraoperative infusion of Esmolol on systemic and pulmonary inflammation in a porcine experimental model of lung resection surgery. Anesth. Analg. 128 (1), 168–175. doi:10.1213/ANE.0000000000003737
Goetz, G., Hawlik, K., and Wild, C. (2021). Extracorporeal cytokine adsorption therapy as a preventive measure in cardiac surgery and as a therapeutic Add-On treatment in sepsis: an updated systematic review of comparative efficacy and safety. Crit. Care Med. 49 (8), 1347–1357. doi:10.1097/CCM.0000000000005023
Goldberger, A. L., Amaral, L. A., Glass, L., Hausdorff, J. M., Ivanov, P. C., Mark, R. G., et al. (2000). PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circulation 101 (23), E215–E220. doi:10.1161/01.cir.101.23.e215
Hasegawa, D., Sato, R., Prasitlumkum, N., and Nishida, K. (2022). Effect of premorbid beta-blockers on mortality in patients with sepsis: a systematic review and meta-analysis. J. Intensive Care Med. 37 (7), 908–916. doi:10.1177/08850666211052926
Howitt, S. H., Herring, M., Malagon, I., McCollum, C. N., and Grant, S. W. (2018). Incidence and outcomes of sepsis after cardiac surgery as defined by the Sepsis-3 guidelines. Br. J. Anaesth. 120 (3), 509–516. doi:10.1016/j.bja.2017.10.018
Hwang, D., Lee, J. M., Kim, H. K., Choi, K. H., Rhee, T. M., Park, J., et al. (2019). Prognostic impact of β-Blocker dose after acute myocardial infarction. Circ. J. 83 (2), 410–417. doi:10.1253/circj.CJ-18-0662
Jia, S., Wang, X., Wang, G., and Wang, X. (2024). Mechanism and application of β-adrenoceptor blockers in soft tissue wound healing. Med. Res. Rev. 44 (1), 422–452. doi:10.1002/med.21984
Johnson, A. E. W., Bulgarelli, L., Shen, L., Gayles, A., Shammout, A., Horng, S., et al. (2023). MIMIC-IV, a freely accessible electronic health record dataset. Sci. Data 10 (1), 1. doi:10.1038/s41597-022-01899-x
Journois, D., Pouard, P., Greeley, W. J., Mauriat, P., Vouhé, P., and Safran, D. (1994). Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components. Anesthesiology 81 (5), 1181–27A. doi:10.1097/00000542-199411000-00011
Kats, S., Schönberger, J. P., Brands, R., Seinen, W., and van Oeveren, W. (2011). Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Eur. J. Cardiothorac. Surg. 39 (4), 451–458. doi:10.1016/j.ejcts.2010.06.011
Klein, D. J., Briet, F., Nisenbaum, R., Romaschin, A. D., and Mazer, C. D. (2011). Endotoxemia related to cardiopulmonary bypass is associated with increased risk of infection after cardiac surgery: a prospective observational study. Crit. Care 15 (1), R69. doi:10.1186/cc10051
Kruk, J., Aboul-Enein, B. H., Bernstein, J., and Gronostaj, M. (2019). Psychological stress and cellular aging in cancer: a meta-analysis. Oxid. Med. Cell Longev. 2019, 1270397. doi:10.1155/2019/1270397
Kuo, M. J., Chou, R. H., Lu, Y. W., Guo, J. Y., Tsai, Y. L., Wu, C. H., et al. (2021). Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patients. J. Intensive Care 9 (1), 40. doi:10.1186/s40560-021-00553-9
Lagrost, L., Girard, C., Grosjean, S., Masson, D., Deckert, V., Gautier, T., et al. (2014). Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass. Crit. Care Med. 42 (5), 1065–1073. doi:10.1097/CCM.0000000000000165
Lindgren, M., Nielsen, S. J., Björklund, E., Pivodic, A., Perrotta, S., Hansson, E. C., et al. (2022). Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study. Eur. Heart J. Cardiovasc Pharmacother. 8 (5), 529–536. doi:10.1093/ehjcvp/pvac006
Lorton, D., and Bellinger, D. L. (2015). Molecular mechanisms underlying β-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int. J. Mol. Sci. 16 (3), 5635–5665. doi:10.3390/ijms16035635
Lowry, S. F. (2005). Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 24 (Suppl. 1), 94–100. doi:10.1097/01.shk.0000191340.23907.a1
Luo, H. (2024). Risk-predictive models for adverse events in cardiac surgery: a review. Cardiovasc. Innovations Appl. 9 (1). doi:10.15212/cvia.2023.0083
Mangoush, O., Purkayastha, S., Haj-Yahia, S., Kinross, J., Hayward, M., Bartolozzi, F., et al. (2007). Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur. J. Cardiothorac. Surg. 31 (6), 1058–1069. doi:10.1016/j.ejcts.2007.01.029
Marik, P. E., and Flemmer, M. (2012). The immune response to surgery and trauma: implications for treatment. J. Trauma Acute Care Surg. 73 (4), 801–808. doi:10.1097/TA.0b013e318265cf87
Martin-Loeches, I., Singer, M., and Leone, M. (2024). Sepsis: key insights, future directions, and immediate goals. A review and expert opinion. Intensive Care Med. 50 (12), 2043–2049. doi:10.1007/s00134-024-07694-z
Ogawa, S., Okawa, Y., Goto, Y., Aoki, M., and Baba, H. (2013). Perioperative use of a beta blocker in coronary artery bypass grafting. Asian Cardiovasc Thorac. Ann. 21 (3), 265–269. doi:10.1177/0218492312451166
Ohri, S. K., Bjarnason, I., Pathi, V., Somasundaram, S., Bowles, C. T., Keogh, B. E., et al. (1993). Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann. Thorac. Surg. 55 (5), 1080–1086. doi:10.1016/0003-4975(93)90011-6
Paparella, D., Yau, T. M., and Young, E. (2002). Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothorac. Surg. 21 (2), 232–244. doi:10.1016/s1010-7940(01)01099-5
Peng, K., Du, B., Si, D., Jin, L., Yang, B., Johnson, N., et al. (2024). IL-6 and D-dimer levels at admission predict cardiac injury and early mortality during SARS-CoV-2 infection. Cardiovasc. Innovations Appl. 9 (1). doi:10.15212/cvia.2024.0009
Pradeep, A., Rangasamy, J., and Varma, P. K. (2021). Recent developments in controlling sternal wound infection after cardiac surgery and measures to enhance sternal healing. Med. Res. Rev. 41 (2), 709–724. doi:10.1002/med.21758
Riddington, D. W., Venkatesh, B., Boivin, C. M., Bonser, R. S., Elliott, T. S., Marshall, T., et al. (1996). Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. Jama 275 (13), 1007–1012. doi:10.1001/jama.1996.03530370045029
Rocke, D. A., Gaffin, S. L., Wells, M. T., Koen, Y., and Brock-Utine, J. G. (1987). Endotoxemia associated with cardiopulmonary bypass. J. Thorac. Cardiovasc Surg. 93 (6), 832–837. doi:10.1016/s0022-5223(19)37043-6
Rudd, K. E., Johnson, S. C., Agesa, K. M., Shackelford, K. A., Tsoi, D., Kievlan, D. R., et al. (2020). Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study. Lancet 395 (10219), 200–211. doi:10.1016/S0140-6736(19)32989-7
Schiller, M., Ben-Shaanan, T. L., and Rolls, A. (2021). Neuronal regulation of immunity: why, how and where? Nat. Rev. Immunol. 21 (1), 20–36. doi:10.1038/s41577-020-0387-1
Sezai, A., Nakai, T., Hata, M., Yoshitake, I., Shiono, M., Kunimoto, S., et al. (2012). Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J. Thorac. Cardiovasc Surg. 144 (5), 1241–1248. doi:10.1016/j.jtcvs.2012.06.042
Smilowitz, N. R., and Berger, J. S. (2020). Perioperative cardiovascular risk assessment and management for noncardiac surgery: a review. Jama 324 (3), 279–290. doi:10.1001/jama.2020.7840
Squiccimarro, E., Labriola, C., Malvindi, P. G., Margari, V., Guida, P., Visicchio, G., et al. (2019). Prevalence and clinical impact of systemic inflammatory reaction after cardiac surgery. J. Cardiothorac. Vasc. Anesth. 33 (6), 1682–1690. doi:10.1053/j.jvca.2019.01.043
Suleiman, M. S., Zacharowski, K., and Angelini, G. D. (2008). Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br. J. Pharmacol. 153 (1), 21–33. doi:10.1038/sj.bjp.0707526
Tan, K., Harazim, M., Simpson, A., Tan, Y. C., Gunawan, G., Robledo, K. P., et al. (2021a). Association between premorbid beta-blocker exposure and sepsis outcomes-the beta-blockers in European and australian/american septic patients (BEAST) study. Crit. Care Med. 49 (9), 1493–1503. doi:10.1097/CCM.0000000000005034
Tan, S., Zhou, F., Zhang, Z., Wang, J., Xu, J., Zhuang, Q., et al. (2021b). Beta-1 blocker reduces inflammation and preserves intestinal barrier function after open abdominal surgery. Surgery 169 (4), 885–893. doi:10.1016/j.surg.2020.11.004
Wang, J. F., Meissner, A., Malek, S., Chen, Y., Ke, Q., Zhang, J., et al. (2005). Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am. J. Physiol. Heart Circ. Physiol. 289 (4), H1577–H1583. doi:10.1152/ajpheart.00258.2005
Whitlock, R. P., Devereaux, P. J., Teoh, K. H., Lamy, A., Vincent, J., Pogue, J., et al. (2015). Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 386 (10000), 1243–1253. doi:10.1016/S0140-6736(15)00273-1
Wong, W. T., Li, L. H., Rao, Y. K., Yang, S. P., Cheng, S. M., Lin, W. Y., et al. (2018). Repositioning of the β-Blocker carvedilol as a novel autophagy inducer that inhibits the NLRP3 inflammasome. Front. Immunol. 9, 1920. doi:10.3389/fimmu.2018.01920
Yang, H. Y., Steenhuis, P., Glucksman, A. M., Gurenko, Z., La, T. D., and Isseroff, R. R. (2021). Alpha and beta adrenergic receptors modulate keratinocyte migration. PLoS One 16 (7), e0253139. doi:10.1371/journal.pone.0253139
Zhang, Y., Li, M., Wang, W., and He, S. (2022). Carvedilol activates nuclear factor E2-related factor 2/antioxidant response element pathway to inhibit oxidative stress and apoptosis of retinal pigment epithelial cells induced by high glucose. Bioengineered 13 (1), 735–745. doi:10.1080/21655979.2021.2012627
Keywords: sepsis, cardiac surgery, perioperative management, MIMIC-IV database, postoperative outcomes
Citation: Yin C, Guan C, Ma Q, Zhang S, Chen Q and Xiao B (2025) Impact of early β-blocker use on the incidence of sepsis and clinical outcomes following cardiac surgery: a retrospective cohort study. Front. Pharmacol. 16:1615868. doi: 10.3389/fphar.2025.1615868
Received: 21 May 2025; Accepted: 21 July 2025;
Published: 30 July 2025.
Edited by:
Yun Yan, Air Force Medical University, ChinaReviewed by:
Yukang Dong, Guizhou Provincial People’s Hospital, ChinaRajesh Madavathazathil Gopalakrishnan, Amrita Vishwa Vidyapeetham, India
Copyright © 2025 Yin, Guan, Ma, Zhang, Chen and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bing Xiao, eGlhb2JpbmdAaGVibXUuZWR1LmNu
†These authors have contributed equally to this work